Search Results
Apr 21, 2025, 08:00 ET Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine anti-A PRoliferation-Inducing Ligand (APRIL) for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial expected in the second half
More news about: Aerovate Therapeutics
Apr 10, 2025, 08:05 ET Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
Response rates continued to improve through Week 24 where 86.4% of adolescents achieved IGA 0/1 (clear or almost clear skin) and 88.6% achieved PASI 90.1 Further, at Week 24, 75% of adolescents achieved IGA 0 (completely clear skin) and 63.6% achieved PASI 100.1 "Data from the
More news about: Johnson & Johnson
Apr 10, 2025, 02:24 ET Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
microbiological fields.Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®.
More news about: Orexo
Apr 10, 2025, 02:21 ET Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
microbiological fields.Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®.
More news about: Orexo
Apr 09, 2025, 16:05 ET Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine anti-A PRoliferation-Inducing Ligand (APRIL) for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial expected in the second half
More news about: Aerovate Therapeutics